Background. Bjork-Shiley convexo-concave heart valves have an increased risk of mechanical failure. One might consider prophylactic rereplacement as a preventive measure to avert the disastrous consequences of these failures. We investigated the effect that prophylactic rereplacement has on survival of individual patients and on the medical costs.
Prophylactic replacement of BScc valves is generally not recommended.3-5 It has been suggested only for patients with early-production 70°BScc valves with a diameter .29 mm (group 1 valves), which are known to be especially vulnerable. 5 The findings in the Dutch follow-up study, however, show that a high risk of strut fracture is not limited to these early-production series of the 700 valves.
In the present study, we evaluate the effects of prophylactic rereplacement using prognostic information obtained from the Dutch follow-up study. For each valve type, the age of the patients is determined below which rereplacement is beneficial. We also evaluated the cost-effectiveness of rereplacement as a function of the patient's age.
Methods

Structure
The structure of the problem is represented by the decision tree shown in Figure 1 . The model contains four health states ("alive with a BScc valve," "alive without a BScc valve," "alive with severe morbidity without a BScc valve," and "dead"). A Markov process was applied to calculate the patient's life expectancy. 6 In a Markov process, the patient's prognosis is represented as a sequence of particular states of health and the possible transitions among them during fixed time intervals (Markov cycle). 7 The duration of the Markov cycle in the present model is 1 year. The crux of this approach is that we estimate after each subsequent year the probability that a patient is in one of the defined health states; in other words, we construct hypothetical survival curves. These survival estimates allow us now to calculate the expected lifetime a patient will spend in each of the health states. The calculations were performed with Decision Maker computer software (New England Medical Center, 1988).
Probability Estimates
The probability estimates required for this analysis were 1) surgical mortality and morbidity after prophylactic rereplacement, 2) age-specific annual risk of death, 3) annual risk of strut fracture, and 4) mortality and morbidity after strut fracture. When possible, these probabilities were derived from the Dutch follow-up study, including 2303 patients with a mean duration of follow-up of 6.6 years. 2 We reanalyzed the data from this study using logistic regression and Poisson regression to derive prognostic models for surgical mortality, age-specific risk of death, and risk of fracture. Variable selection was performed with a forward stepwise procedure based on the significance level of the partial likelihood ratio test (limit for significance to enter, 0.10). First, we estimated the effects of prophylactic rereplacement for patients without comorbidity. Later, we explored to some extent the effect of comorbidity, such as a poor ventricular function.
Surgical Mortality and Morbidity of Prophylactic Rereplacement
Data about the risks associated with prophylactic replacement of artificial valves are scarce.8,9 It has been emphasized that, when estimating the risks of prophylactic rereplacement, one must take into account not only the increased hazard for death during the early postoperative period (for example, the first 30 days after surgery) but also the increased hazard during the entire first postoperative year.3 This opinion, however, is not supported by the observation that mortality after rereplacement for reasons other than an increased risk of mechanical failure seems to decline rapidly to a constant level even after 2 weeks.10 Therefore, we defined surgical mortality of rereplacement as that occurring during the first 30 days after surgery. Furthermore, we assumed it to be equivalent to the 30-day mortality after primary valve replacement. Surgical mortality after rereplacement is then estimated with a logistic model derived from the Dutch follow-up study. Surgical mortality for a 40-year-old patient without any risk factor is 1.5% (odds, 0.015). Age (odds ratio, 1.022; 95% CI, 1 Table 1 ). For example, the annual risk of reported patients, 18 died (51%). These mortality rates were adopted in the present analysis. It is assumed that 50% of the survivors of an outlet strut fracture will have severe permanent morbidity. This estimate is based on an evaluation of the functional status of the Dutch patients who survived the outlet strut fracture.
Outcomes
We calculated life expectancy with and without replacement of the BScc valve. To account for the fact that most patients are risk averse (in other words, they attach more value to nearby years of life than to years of life in the distant future), we investigated the effects of discounting future life years at 5% per year13 (this implies that the value of each additional year decreases by 5%) and also the effects of adjusting for the quality of life by weighing the time spent with severe permanent morbidity from valve surgery or outlet strut fracture with a quality adjustment factor of 0.5 (each year for a patient with severe morbidity is worth half a year in full health).
We represent the direct medical costs for rereplacement and expectant management in 1990 Dutch guilders (f)14-16 ($1 US was approximately f2). The costs of prophylactic rereplacement are estimated to be f20 000 (angiography, surgery, 3 days in intensive care, and 10 days in low care). The costs of an outlet strut fracture amount to f15 000 for a patient who dies after admission to hospital (surgery and 5 days intensive care). Furthermore, it is assumed that 50% of the patients who die after an outlet strut fracture die outside the hospital. The costs for patients who survive after an outlet strut fracture are f45 000 (surgery for valve replacement, 5 days in intensive care, and 20 days in low care followed by surgery for removal of the fractured strut, 1 day in intensive care, and 12 days in low care). Future costs were discounted to present value at a 5% per year discount rate.
Simplifications
Our analysis was subject to the following simplifying assumptions: 1) the surgical mortality of prophylactic rereplacement is equivalent to the 30-day mortality after primary valve replacement; 2) survival of patients with an artificial valve is determined by their attained age and clinical condition and not by the time elapsed since primary valve replacement; 3) replacement of the Figure 3 presents the effects of variations in the preferences for length and quality of life. The difference in discounted life expectancy decreases to zero if the discount rate of future years of life increases from 0% to 10%. If the quality adjustment factor decreases from one (morbidity is equivalent with full health) to zero (morbidity is equivalent with death), the advantageous effect of rereplacement increases.
In Figure 4 , the age thresholds for prophylactic replacement of BScc valves are shown for patients without comorbidity. For each valve type, we calculated age thresholds, first using simple future years of life, second using discounted years of life, and third using discounted and quality-adjusted years of life. To account for the statistical uncertainty, we indicated CIs for these age thresholds using the upper and lower limits of the 95% CI of the estimated strut fracture risk. It can be read from Figure 4A that life expectancy (in simple future years of life) for male patients with a small 60°mitral valve is higher with than without prophylactic rereplacement if they are <27 years old. For male patients with a 600 large mitral BScc valve, this age threshold is 48 years. The age thresholds are considerably higher for valves with an opening angle of 70°: 51 and 65 years for small and large mitral valves, respectively. The age thresholds for aortic valves are somewhat higher than for mitral valves. They are 39 and 52 years for small and large 60°aortic valves and 56 and 76 years for small and large 700 BScc aortic valves, respectively. For female patients, all age thresholds lie 1 or 2 years higher ( Figure 4B ).
The effect of discounting future years of life and adjusting for the quality of life on the age thresholds is relatively small for most valve types. Only for small 600 valves in either the mitral or aortic position do the age thresholds decrease considerably when discounted future years of life are used.
The age thresholds presented so far are based on the assumption that surgical mortality for prophylactic rereplacement is the same as that after primary valve replacement. In Figure SA, . These figures present the age thresholds if 0% (a), 1% (a), or 3% (A) is added to the surgical mortality and morbidity. Thus, the surgical mortality is estimated with a logistic model as a function of age and clinical risk factors (see "Methods"), and to this risk estimate, a fixed extra risk of 1% or 3% is added. For each valve type, age thresholds are based on simple years of life, discounted years of life, and discounted and quality-adjusted years of life (from left to right). A horizontal line at age 0 years indicates that no age threshold could be found.
70 small 70 large (group 1, 70°BScc valves).5 Our study indicates that patients with other BScc valve types also may benefit from prophylactic rereplacement. Prophylactic replacement of BScc valves may increase the discounted and quality-adjusted life expectancy in patients without comorbidity with large 60°mitral and aortic BScc valves if they are <45 years old and in patients with small 700 mitral and aortic valves if they are <50 years old. The age thresholds for prophylactic replacement are high for aortic BScc valves, considering the relatively low strut fracture risk is taken into account. The explanation for this result is the high mortality after aortic strut fracture on the one hand and the relatively low surgical risks and high life expectancy in patients with aortic valves on the other. The slightly higher age thresholds that we established for female patients are explained by the higher basal life expectancy of female patients. The costeffectiveness of prophylactic rereplacement depends strongly on age, valve type, and valve position. This is to be expected, because these factors determine the extent of the survival advantage of valve replacement.
If the surgical risks after prophylactic rereplacement are thought to be higher than after primary replacement, however, the age thresholds below which prophylactic rereplacement prolongs discounted and qualityadjusted survival decrease considerably for the large 600 and small 700 aortic valves and to a lesser extent for the large 600 mitral BScc valve. Conceivably, the age thresholds for prophylactic replacement are also significantly lower if a comorbid factor, such as a poor left ventricular function, is present. For patients with a large 70°B Scc valve, however, with its high risk of strut fracture, the effect of comorbidity on age thresholds is small.
In a recent study, Birkmeyer and coworkers reported the operative risk thresholds below which replacement of a BScc valve increases life expectancy expressed in simple future years of life.'7 The estimates of the fracture rate in this study were derived from Dutch and Swedish follow-up studies and from an international multi-institutional follow-up study of patients with 700 BScc valves.2,3'18 The strut fracture risks they used for the 70°mitral valve were on average about 40% lower than we used in our study, and their fracture risks for 600 aortic valves were more than twice as high as ours. Their recommendations for rereplacement agree with 4 .1% and 5.6% for 80-year-old male and female patients, respectively). Furthermore, this study confirms our conclusion that rereplacement of the large 60" mitral valves may be advantageous in patients without comorbidity up to 45 years old. The high operative risk thresholds for older patients in the study of Birkmeyer and coworkers can be partly explained by their assumption that the strut fracture rates are age independent, whereas the Dutch follow-up study indicated a strong decrease of the strut fracture rates with age at implantation.
In our study, we derived quantitative estimates from a detailed multivariate analysis of the Dutch follow-up study. This allowed us to develop prognostic models for valve fracture as well as for surgical mortality and life expectancy. Another reason for not using the results of studies from different countries on the strut fracture rate is some indication that the fracture rate depends on batch-related manufacturing deficiencies and that different countries have received different production series.1219 In our view, this implies that recommendations on prophylactic rereplacement have to take into account the batch-specific strut fracture risk estimates. 20 When interpreting the results of the present study, one must also take into account the possibility that a number of strut fractures have remained undetected,23 leading to an underestimate of the risk of strut fracture as well as of mortality from strut fracture. Another element of uncertainty in this respect is the risk of strut fracture in the distant future. Our estimations of the effect of rereplacement are based on a constant fracture risk over time, which is supported by observations during the follow-up period and also by metallurgical investigations that indicated fatigue at the welding sites of the outlet strut as a possible cause of fracture.21.22 If a distinct rise or fall in the number of strut fractures is observed in the future, however, the indications for replacement of the BScc valves have to be adjusted accordingly. It is shown in our study that variations in the annual risk of strut fracture have a considerable effect on indications for prophylactic rereplacement (see Figure 2) .
When considering prophylactic replacement of BScc heart valves, the patient and his or her doctor have to balance the consequences of cardiac surgery against the possibility that a strut fracture may occur at some moment in the future, with its associated high mortality. In general, most patients tend to be risk averse and consider current benefits preferable to future benefits. 13 In other words, they consider life during the next few months more important than during later years. Therefore, we also estimated the age thresholds discounting future years of life. In addition to this attitude toward the surgical risk, a patient may wish the BScc valve to be replaced because of the fear and anxiety evoked by the possibility that the artificial valve may fail mechanically. This risk attitude is not explicitly modeled in our study. In this respect, however, it is important to note that mechanical failure is only one of the dangers that threaten patients with artificial heart valves. 23 8 compared with 34.9 years) . Finally, one has to account for postoperative morbidity, which may interfere with a patient's normal activities of daily life during at least a few months.
The results of the Dutch follow-up study allow recommendations for prophylactic replacement of the BScc valves. The age thresholds presented in this study may serve as rough guidelines for patient selection but can never substitute for definitive decision making, which should be based on an individual evaluation of the strut fracture rate (which may vary between countries), risks of surgery, life expectancy, and the patient's attitude toward the alternative options.
